Skip to main content
SpringerLink
Log in

Schnitzler syndrome

Schnitzler-Syndrom

  • Übersichten
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Abstract

Schnitzler syndrome is a very rare acquired systemic disease with many similarities to hereditary autoinflammatory syndromes. The main characteristics are generalized exanthema and IgM monoclonal gammopathy. Other clinical features include fever, muscle, bone, and/or joint pain, and lymphadenopathy. About 15–20% of patients with Schnitzler syndrome develop lymphoproliferative diseases and, in rare cases, amyloid A (AA) amyloidosis can occur if the disease is not treated. Activation of the innate immune system, especially interleukin (IL)-1β, is central to the pathogenesis of disease. Consequently, complete control of disease symptoms can be achieved in 80% of patients by treatment with the IL-1 receptor antagonist anakinra.

Zusammenfassung

Das Schnitzler-Syndrom ist eine sehr seltene, erworbene Systemerkrankung, die viele Gemeinsamkeiten mit den hereditären autoinflammatorischen Syndromen aufweist. Das Exanthem und eine monoklonale Gammopathie mit IgM sind die Charakteristika der Erkrankung. Zu den klinischen Hauptmerkmalen gehören Fieber, urtikarielles Exanthem, Muskel‑, Knochen- und/oder Gelenkschmerzen und eine Lymphadenopathie. Etwa 15–20 % der Patienten mit Schnitzler-Syndrom entwickeln eine lymphoproliferative Erkrankung, und selten kann es zum Auftreten einer AA-Amyloidose kommen, wenn die Erkrankung nicht behandelt wird. Eine Aktivierung des angeborenen Immunsystems, speziell des Interleukin(IL)-1β, ist zentral in der Pathogenese der Erkrankung. Folgerichtig kann bei 80 % der Patienten eine komplette Kontrolle der Krankheitssymptome durch Behandlung mit dem IL-1-Rezeptorantagonisten Anakinra erreicht werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lipsker D (2010) The Schnitzler syndrome. Orphanet J Rare Dis 5:38. https://doi.org/10.1186/1750-1172-5-38

    Article  PubMed  PubMed Central  Google Scholar 

  2. Simon A, Asli B, Braun-Falco M et al (2013) Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy 68:562–568. https://doi.org/10.1111/all.12129

    Article  CAS  PubMed  Google Scholar 

  3. Schnitzler L (1972) Lesions urticariennes chroniques permanentes (erytheme petaloide?). Case cliniques n. 46 B. Jounee Dermatologique d’Angers

  4. de Koning HD, Bodar EJ, van der Meer JWM et al (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37:137–148. https://doi.org/10.1016/j.semarthrit.2007.04.001

    Article  PubMed  Google Scholar 

  5. Krause K, Grattan CE, Bindslev-Jensen C et al (2012) How not to miss autoinflammatory diseases masquerading as urticaria. Allergy 67:1465–1474. https://doi.org/10.1111/all.12030

    Article  CAS  PubMed  Google Scholar 

  6. Lipsker D, Veran Y, Grunenberger F et al (2001) The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 80:37–44

    Article  CAS  Google Scholar 

  7. Venzor J, Lee WL, Huston DP (2002) Urticarial vasculitis. Clin Rev Allergy Immunol 23:201–216. https://doi.org/10.1385/CRIAI:23:2:201

    Article  PubMed  Google Scholar 

  8. Kuemmerle-Deschner JB (2015) CAPS—pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol 37:377–385. https://doi.org/10.1007/s00281-015-0491-7

    Article  CAS  PubMed  Google Scholar 

  9. Germain P, Fach J, Bui N et al (2000) Schnitzler syndrome: a rare cause of systemic urticaria. Rev Med Interne 21:285–289

    Article  CAS  Google Scholar 

  10. Asli B, Brouet JC, Fermand JP (2011) Spontaneous remission of Schnitzler syndrome. Ann Allergy Asthma Immunol 107:87–88. https://doi.org/10.1016/j.anai.2011.04.006

    Article  PubMed  Google Scholar 

  11. Dalle S, Balme B, Sebban C et al (2006) Schnitzler syndrome associated with systemic marginal zone B‑cell lymphoma. Br J Dermatol 155:827–829. https://doi.org/10.1111/j.1365-2133.2006.07417.x

    Article  CAS  PubMed  Google Scholar 

  12. Bonnekoh H, Krause K (2017) Das Schnitzler-Syndrom – eine seltene Differenzialdiagnose und interdisziplinäre Herausforderung. Aktuelle Rheumatol 42:53–58. https://doi.org/10.1055/s-0042-124094

    Article  Google Scholar 

  13. Gusdorf L, Asli B, Barbarot S et al (2017) Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients. Allergy 72:177–182. https://doi.org/10.1111/all.13035

    Article  CAS  PubMed  Google Scholar 

  14. Broekaert SMC, Böer-Auer A, Kerl K et al (2016) Neutrophilic epitheliotropism is a histopathological clue to neutrophilic urticarial dermatosis. Am J Dermatopathol 38:39–49. https://doi.org/10.1097/DAD.0000000000000390

    Article  PubMed  Google Scholar 

  15. Terpos E, Asli B, Christoulas D et al (2012) Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. Haematologica 97:1699–1703. https://doi.org/10.3324/haematol.2012.067306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. de Koning HD, Schalkwijk J, Stoffels M et al (2015) The role of interleukin-1 beta in the pathophysiology of Schnitzler’s syndrome. Arthritis Res Ther 17:187. https://doi.org/10.1186/s13075-015-0696-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Krause K, Tsianakas A, Wagner N et al (2017) Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. J Allergy Clin Immunol 139:1311–1320. https://doi.org/10.1016/j.jaci.2016.07.041

    Article  CAS  PubMed  Google Scholar 

  18. Zuberbier T, Aberer W, Asero R et al (2014) The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 69:868–887. https://doi.org/10.1111/all.12313

    Article  CAS  PubMed  Google Scholar 

  19. Bonnekoh H, Scheffel J, Kambe N, Krause K (2018) The role of mast cells in autoinflammation. Immunol Rev 282:265–275. https://doi.org/10.1111/imr.12633

    Article  CAS  PubMed  Google Scholar 

  20. Peroni A, Colato C, Zanoni G, Girolomoni G (2010) Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part II. Systemic diseases. J Am Acad Dermatol 62:557–570. https://doi.org/10.1016/j.jaad.2009.11.687 (quiz 571–572)

    Article  PubMed  Google Scholar 

  21. Kieffer C, Cribier B, Lipsker D (2009) Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 88:23–31. https://doi.org/10.1097/MD.0b013e3181943f5e

    Article  Google Scholar 

  22. Ehrchen J (2016) Neutrophile urtikarielle Dermatose(n). Hautarzt 67:403–413. https://doi.org/10.1007/s00105-016-3788-0

    Article  CAS  PubMed  Google Scholar 

  23. Hedrich CM, Günther C, Aringer M (2017) Still’s disease in children and adults. Z Rheumatol 76:595–608. https://doi.org/10.1007/s00393-017-0358-5

    Article  CAS  PubMed  Google Scholar 

  24. Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 27:621–668. https://doi.org/10.1146/annurev.immunol.25.022106.141627

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ryan JG, de Koning HD, Beck LA et al (2008) IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 121:260–262. https://doi.org/10.1016/j.jaci.2007.09.021

    Article  CAS  PubMed  Google Scholar 

  26. de Koning HD, van Vlijmen-Willems IMJJ, Rodijk-Olthuis D et al (2015) Mast-cell interleukin-1β, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler’s syndrome. Br J Dermatol 173:448–456. https://doi.org/10.1111/bjd.13857

    Article  CAS  PubMed  Google Scholar 

  27. Zielinski CE, Mele F, Aschenbrenner D et al (2012) Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 484:514–518. https://doi.org/10.1038/nature10957

    Article  CAS  PubMed  Google Scholar 

  28. Noster R, de Koning HD, Maier E et al (2016) Dysregulation of proinflammatory versus anti-inflammatory human TH17 cell functionalities in the autoinflammatory Schnitzler syndrome. J Allergy Clin Immunol 138:1161–1169.e6. https://doi.org/10.1016/j.jaci.2015.12.1338

    Article  CAS  PubMed  Google Scholar 

  29. Krause K, Feist E, Fiene M et al (2012) Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 129:848–850. https://doi.org/10.1016/j.jaci.2011.10.031

    Article  PubMed  Google Scholar 

  30. Gusdorf L, Lipsker D (2017) Schnitzler syndrome: a review. Curr Rheumatol Rep. https://doi.org/10.1007/s11926-017-0673-5

    Article  PubMed  Google Scholar 

  31. Rowczenio DM, Pathak S, Arostegui JI et al (2018) Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. Blood 131:974–981. https://doi.org/10.1182/blood-2017-10-810366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Treon SP, Xu L, Yang G et al (2012) MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 367:826–833. https://doi.org/10.1056/NEJMoa1200710

    Article  CAS  PubMed  Google Scholar 

  33. Néel A, Henry B, Barbarot S et al (2014) Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: A french multicenter study. Autoimmun Rev 13:1035–1041. https://doi.org/10.1016/j.autrev.2014.08.031

    Article  CAS  PubMed  Google Scholar 

  34. Krause K, Weller K, Stefaniak R et al (2012) Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 67:943–950. https://doi.org/10.1111/j.1398-9995.2012.02843.x

    Article  CAS  PubMed  Google Scholar 

  35. de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J et al (2013) Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann Rheum Dis 72:1634–1638. https://doi.org/10.1136/annrheumdis-2012-202192

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University Hospital Dresden, Fetscherstr. 74, 01307, Dresden, Germany

    F. F. Gellrich & C. Günther

Authors
  1. F. F. Gellrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Günther
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. F. Gellrich.

Ethics declarations

Conflict of interest

F. F. Gellrich and C. Günther declare that they have no competing interests.

For this article, no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gellrich, F.F., Günther, C. Schnitzler syndrome. Hautarzt (2019). https://doi.org/10.1007/s00105-019-4434-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s00105-019-4434-4

Keywords

Schlüsselwörter

Search

Navigation